featured
Lenalidomide–Epoetin Alfa vs Lenalidomide Monotherapy in MDS Refractory to Recombinant Erythropoietin
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
J. Clin. Oncol 2021 Jan 13;[EPub Ahead of Print], AF List, Z Sun, A Verma, JM Bennett, RS Komrokji, K McGraw, J Maciejewski, JK Altman, PS Cheema, DF Claxton, SM Luger, RJ Mattison, TR Wassenaar, AS Artz, CA Schiffer, MR Litzow, MS TallmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.